Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model

1998 ◽  
Vol 46 (1) ◽  
pp. 21-24 ◽  
Author(s):  
N. K. Egilmez ◽  
Yong S. Jong ◽  
Yoshimi Iwanuma ◽  
Jules S. Jacob ◽  
Camilla A. Santos ◽  
...  
Keyword(s):  
Controlled Release ◽  
Mouse Model ◽  
Scid Mouse ◽  
Human Tumor ◽  
Tumor Xenograft ◽  
Biodegradable Microspheres ◽  
Human Tumor Xenograft ◽  
Immunotherapy Of Cancer ◽  
Scid Mouse Model

scholarly journals Force estimation from 4D OCT data in a human tumor xenograft mouse model

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Maximilian Neidhardt ◽  
Nils Gessert ◽  
Tobias Gosau ◽  
Julia Kemmling ◽  
Susanne Feldhaus ◽  
...  
Keyword(s):  
Deep Learning ◽  
Mouse Model ◽  
Haptic Feedback ◽  
Human Tumor ◽  
Tumor Xenograft ◽  
Human Tumor Xenograft ◽  
Force Estimation ◽  
Xenograft Mouse Model ◽  
Dead Tissue

AbstractMinimally invasive robotic surgery offer benefits such as reduced physical trauma, faster recovery and lesser pain for the patient. For these procedures, visual and haptic feedback to the surgeon is crucial when operating surgical tools without line-of-sight with a robot. External force sensors are biased by friction at the tool shaft and thereby cannot estimate forces between tool tip and tissue. As an alternative, vision-based force estimation was proposed. Here, interaction forces are directly learned from deformation observed by an external imaging system. Recently, an approach based on optical coherence tomography and deep learning has shown promising results. However, most experiments are performed on ex-vivo tissue. In this work, we demonstrate that models trained on dead tissue do not perform well in in vivo data. We performed multiple experiments on a human tumor xenograft mouse model, both on in vivo, perfused tissue and dead tissue. We compared two deep learning models in different training scenarios. Training on perfused, in vivo data improved model performance by 24% for in vivo force estimation.

Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype

1996 ◽  
Vol 37 (4) ◽  
pp. 305-316 ◽  
Author(s):  
W. T. Bellamy ◽  
Pamela Mendibles ◽  
Petra Bontje ◽  
Floyd Thompson ◽  
Lynne Richter ◽  
...  
Keyword(s):  
Scid Mouse ◽  
Xenograft Model ◽  
Human Tumor ◽  
Multidrug Resistant ◽  
Tumor Xenograft ◽  
Human Tumor Xenograft ◽  
Resistant Phenotype ◽  
Human Tumor Xenograft Model

scholarly journals DDIS-29. BRAIN-PENETRANT MICROTUBULE-TARGETING AGENT, ST-401, KILLS GLIOBLASTOMA THROUGH A NOVEL MECHANISM

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi69-vi69
Author(s):  
Eric Horne ◽  
Cong Xu ◽  
Juan-Jesus Vicente ◽  
P J Cimino ◽  
Michael Wagenbach ◽  
...  
Keyword(s):  
Overall Survival ◽  
Mouse Model ◽  
Human Tumor ◽  
Maximum Tolerated Dose ◽  
Tumor Xenograft ◽  
Human Tumor Xenograft ◽  
Glioblastoma Cells ◽  
Cells In Culture ◽  
Microtubule Targeting Agents ◽  
Mouse Model System

Abstract Glioblastomas are particularly sensitive to mitotic disruption when compared with nonmalignant cells and thus microtubule-targeting agents (MTA) represent promising therapeutics to treat patients with glioblastomas; but few such compounds pass the blood brain barrier. We developed a series of modified carbazoles, evaluated their anti-cancer activity in glioblastoma cells in culture and identified ST-401 as the most potent compound (IC50, 10 – 102 nM, depending on the cell line). Testing of ST-401 on the NCI 60 cancer cell panel indicated that its anti-tumor activity does not correlate with any of the compounds tested thus far through this platform but showed weak correlations for taxol (p=0.46) and vinblastine (p=0.34). Thus, ST-401 may kill cancer cells through a novel mechanism related to disruption of MT function. Biochemical analysis indicates that ST-401 binds to the colchicine site of tubulin and inhibits tubulin assembly. Real-time imaging of MT dynamics in cells in culture shows that ST-401 reduces MT assembly rates but in a reversible fashion. ST-401 potently blocks mitotic progression and triggers cell death in multiple glioblastoma lines in culture, including patient-derived glioblastomas of the proneural, mesenchymal and classical subtypes. We established the maximum tolerated dose (MTD) of ST-401 in mice (20 mg/kg/bdip) and found that its acute i.p. injection results in micromolar amounts of ST-401 in mouse brain. Using this treatment regimen, we found that ST-401 reduces tumor growth and doubles overall survival in a human tumor xenograft mouse model system. ST-401 also increases by 2-fold overall survival in the genetic RCAS-PDGF glioblastomas mouse model treated with standard care (radiation and Temodar® treatments). Histological analysis of RCAS-PDGF glioblastoma tissue shows that ST-401 triggers mitotic arrest of glioblastoma cells. ST-401 represents a promising lead compound for the treatments for patients diagnosed with glioblastomas.

scholarly journals Virus and Autoantigen-Specific CD4+ T Cells Are Key Effectors in a SCID Mouse Model of EBV-Associated Post-Transplant Lymphoproliferative Disorders

2014 ◽  
Vol 10 (5) ◽  
pp. e1004068 ◽  
Author(s):  
Stefanie Linnerbauer ◽  
Uta Behrends ◽  
Dinesh Adhikary ◽  
Klaus Witter ◽  
Georg W. Bornkamm ◽  
...  
Keyword(s):  
T Cells ◽  
Mouse Model ◽  
Cd4 T Cells ◽  
Scid Mouse ◽  
Lymphoproliferative Disorders ◽  
Post Transplant ◽  
Scid Mouse Model
Sign in / Sign up

Export Citation Format

Share Document